Cancer glycobiology is a blazing hot area of cancer research with aberrant post-translational glycosylations on lipids and proteins considered critical for cancer development and metastasis. The NIH/NCI Alliance of Glycobiologists for Cancer Research is a consortium of (10) tumor glycobiology laboratories funded to investigate how cancer-associated glycans (CAG) impact the development and metastasis of cancer. The hope of this momentous effort is to discover CAGs for use as novel biomarkers to detect early-stage cancer or its aggressive behavior or, alternatively, as novel molecular targets with the promise of a curative approach to cancer therapy. The mission of the ‘Alliance’ is to study structure and function of CAGs in cancer development and to provide clinically useful biomarkers for detecting cancer early or the potential of metastasis. This charge has stimulated extensive collaborations across US and International institutions to accelerate discovery of glycan-based biomarkers to the forefront of NCI's efforts to diagnose early-stage cancer and provide curative anti-cancer therapies.
The main goals of these research efforts are: 1. To identify and study how cancer-associated glycans functionally impact cancer growth and metastasis 2. To identify cancer-associated glycans that can serve as biomarkers for the detection or progression of cancer 3. To develop cancer-associated glycans as novel therapeutic targets for the treatment and cure of cancer
This volume consists of (9) chapters, one from each funded laboratory, that reviews new methods and mechanisms highlighting glycoconjugates and their roles as cancer biomarkers and/or anti-cancer therapeutic targets.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright page - p. iii 5. Contributors - p. iii 6. Collaborative Spirit Drives the Field of Tumor Glycobiology: A Preface to Special Volume on Cancer Glycobiology - p. iii 7. Chapter One: The clinical role of glycobiology on ovarian cancer progression - p. 1 8. Chapter Two: Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach - p. 23 9. Chapter Three: Beyond glyco-proteomics—Understanding the role of genetics in cancer biomarkers - p. 57 10. Chapter Four: Measuring the multifaceted roles of mucin-domain glycoproteins in cancer - p. 83 11. Chapter Five: Role of tumor cell sialylation in pancreatic cancer progression - p. 123 12. Chapter six: The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma - p. 157 13. Chapter Seven: Role of O-GlcNAcylation on cancer stem cells: Connecting nutrient sensing to cell plasticity - p. 195 14. Chapter Eight: The biology of E-selectin ligands in leukemogenesis - p. 229 15. Chapter Nine: Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential - p. 251
Cancer glycobiology is a blazing hot area of cancer research with aberrant post-translational glycosylations on lipids and proteins considered critical for cancer development and metastasis. The NIH/NCI Alliance of Glycobiologists for Cancer Research is a consortium of (10) tumor glycobiology laboratories funded to investigate how cancer-associated glycans (CAG) impact the development and metastasis of cancer. The hope of this momentous effort is to discover CAGs for use as novel biomarkers to detect early-stage cancer or its aggressive behavior or, alternatively, as novel molecular targets with the promise of a curative approach to cancer therapy. The mission of the ‘Alliance’ is to study structure and function of CAGs in cancer development and to provide clinically useful biomarkers for detecting cancer early or the potential of metastasis. This charge has stimulated extensive collaborations across US and International institutions to accelerate discovery of glycan-based biomarkers to the forefront of NCI's efforts to diagnose early-stage cancer and provide curative anti-cancer therapies.
The main goals of these research efforts are: 1. To identify and study how cancer-associated glycans functionally impact cancer growth and metastasis 2. To identify cancer-associated glycans that can serve as biomarkers for the detection or progression of cancer 3. To develop cancer-associated glycans as novel therapeutic targets for the treatment and cure of cancer
This volume consists of (9) chapters, one from each funded laboratory, that reviews new methods and mechanisms highlighting glycoconjugates and their roles as cancer biomarkers and/or anti-cancer therapeutic targets.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright page - p. iii 5. Contributors - p. iii 6. Collaborative Spirit Drives the Field of Tumor Glycobiology: A Preface to Special Volume on Cancer Glycobiology - p. iii 7. Chapter One: The clinical role of glycobiology on ovarian cancer progression - p. 1 8. Chapter Two: Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach - p. 23 9. Chapter Three: Beyond glyco-proteomics—Understanding the role of genetics in cancer biomarkers - p. 57 10. Chapter Four: Measuring the multifaceted roles of mucin-domain glycoproteins in cancer - p. 83 11. Chapter Five: Role of tumor cell sialylation in pancreatic cancer progression - p. 123 12. Chapter six: The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma - p. 157 13. Chapter Seven: Role of O-GlcNAcylation on cancer stem cells: Connecting nutrient sensing to cell plasticity - p. 195 14. Chapter Eight: The biology of E-selectin ligands in leukemogenesis - p. 229 15. Chapter Nine: Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential - p. 251
